Cargando…
Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection
Chagas disease (CD), caused by Trypanosoma cruzi, affects approximately 6 to 7 million people in Latin America, with cardiomyopathy being the clinical manifestation most commonly associated with patient death during the acute phase. The etiological treatment of CD is restricted to benznidazole (Bz)...
Autores principales: | Barbosa, Juliana Magalhães Chaves, Pedra Rezende, Yasmin, de Melo, Tatiana Galvão, de Oliveira, Gabriel, Cascabulho, Cynthia Machado, Pereira, Evelyn Nunes Goulart da Silva, Daliry, Anissa, Salem, Kelly Salomão |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826820/ https://www.ncbi.nlm.nih.gov/pubmed/35138142 http://dx.doi.org/10.1128/spectrum.01852-21 |
Ejemplares similares
-
Benznidazole and amiodarone combined treatment attenuates cytoskeletal damage in Trypanosoma cruzi-infected cardiac cells
por: Barbosa, Juliana Magalhães Chaves, et al.
Publicado: (2022) -
Benznidazole Treatment: Time- and Dose-Dependence Varies with the Trypanosoma cruzi Strain
por: Fonseca, Kátia da Silva, et al.
Publicado: (2021) -
Transcriptomic analysis of benznidazole-resistant and susceptible Trypanosoma cruzi populations
por: Lima, Davi Alvarenga, et al.
Publicado: (2023) -
Combined Treatment of Heterocyclic Analogues and Benznidazole upon Trypanosoma cruzi In Vivo
por: Batista, Denise da Gama Jaén, et al.
Publicado: (2011) -
Benznidazole Biotransformation and Multiple Targets in Trypanosoma cruzi Revealed by Metabolomics
por: Trochine, Andrea, et al.
Publicado: (2014)